NASDAQ:ANIP - ANI Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $46.00
  • Forecasted Upside: 39.35 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$33.01
▼ -1.02 (-3.00%)
1 month | 3 months | 12 months
Get New ANI Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANIP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANIP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$46.00
▲ +39.35% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ANI Pharmaceuticals in the last 3 months. The average price target is $46.00, with a high forecast of $58.00 and a low forecast of $40.00. The average price target represents a 39.35% upside from the last price of $33.01.
Buy
The current consensus among 3 polled investment analysts is to buy stock in ANI Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/3/2020Raymond JamesLower Price TargetOutperform$49.00 ➝ $40.00Low
i
5/8/2020Raymond JamesLower Price TargetOutperform$65.00 ➝ $49.00Medium
i
5/7/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$78.00 ➝ $40.00High
i
Rating by B. Folkes at Cantor Fitzgerald
4/30/2020GuggenheimLower Price TargetBuy$62.00 ➝ $58.00Medium
i
2/28/2020Raymond JamesLower Price TargetOutperform$75.00 ➝ $65.00Medium
i
9/12/2019GuggenheimInitiated CoverageBuy$76.00High
i
5/13/2019Canaccord GenuityReiterated RatingPositive ➝ Buy$80.00 ➝ $90.00High
i
5/10/2019Raymond JamesDowngradeStrong-Buy ➝ Outperform$73.00 ➝ $82.00Low
i
Rating by Elliot Wilbur at Raymond James
5/9/2019Cantor FitzgeraldReiterated RatingBuy$89.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
2/28/2019Raymond JamesSet Price TargetBuy$73.00Medium
i
Rating by Elliot Wilbur at Raymond James
12/28/2018Cantor FitzgeraldSet Price TargetBuy$74.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
11/9/2018Canaccord GenuitySet Price TargetBuy ➝ Buy$75.00 ➝ $70.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
11/6/2018Cantor FitzgeraldSet Price TargetBuy$74.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
10/3/2018Cantor FitzgeraldSet Price TargetBuy$74.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/16/2018Canaccord GenuitySet Price TargetBuy ➝ Buy$82.00 ➝ $75.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
8/7/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Buy$85.00 ➝ $74.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
6/27/2018Canaccord GenuityReiterated RatingBuy$82.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$85.00Low
i
5/8/2018Canaccord GenuitySet Price TargetBuy$82.00High
i
Rating by Dewey Steadman at Canaccord Genuity
2/27/2018Canaccord GenuitySet Price TargetBuy ➝ Buy$77.00 ➝ $82.00High
i
Rating by Dewey Steadman at Canaccord Genuity
12/29/2017Canaccord GenuitySet Price TargetBuy$77.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
12/9/2017Canaccord GenuitySet Price TargetBuy$75.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
11/2/2017Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Dewey Steadman at Canaccord Genuity
10/16/2017Canaccord GenuityReiterated RatingBuy ➝ Buy$60.00 ➝ $66.00N/A
i
Rating by Dewey Steadman at Canaccord Genuity
8/9/2017Canaccord GenuityReiterated RatingBuy$60.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
7/31/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$60.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
7/4/2017GuggenheimReiterated RatingBuy$80.00Low
i
Rating by Louise Chen at Guggenheim
5/6/2017Roth CapitalSet Price TargetHold$56.00Low
i
Rating by Scott Henry at Roth Capital
4/6/2017GuggenheimReiterated RatingBuy$80.00High
i
3/4/2017Roth CapitalSet Price TargetHold$56.00N/A
i
Rating by Scott Henry at Roth Capital
3/3/2017GuggenheimReiterated RatingNeutral$80.00N/A
i
2/22/2017Roth CapitalDowngradeBuy ➝ Neutral$69.00N/A
i
Rating by S. Henry at Roth Capital
8/5/2016GuggenheimReiterated RatingBuy$65.00 ➝ $80.00N/A
i
8/5/2016OppenheimerBoost Price TargetOutperform$65.00 ➝ $71.00N/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
7/19/2016CitigroupUpgradeOutperform$65.00N/A
i
7/8/2016CitigroupDowngradeOutperform ➝ Market Perform$49.00N/A
i
6/22/2016Raymond JamesInitiated CoverageStrong-Buy$68.00N/A
i
6/17/2016GuggenheimReiterated RatingBuy$55.00 ➝ $65.00N/A
i
5/24/2016Standpoint ResearchDowngradeBuy ➝ HoldN/A
i
5/7/2016GuggenheimReiterated RatingBuy$50.00 ➝ $55.00N/A
i
5/3/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
(Data available from 4/21/2016 forward)
ANI Pharmaceuticals logo
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Read More

Today's Range

Now: $33.01
$32.05
$34.91

50 Day Range

MA: $32.46
$28.40
$36.14

52 Week Range

Now: $33.01
$23.55
$48.45

Volume

65,672 shs

Average Volume

57,346 shs

Market Capitalization

$408.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of ANI Pharmaceuticals?

The following equities research analysts have issued research reports on ANI Pharmaceuticals in the last twelve months: Cantor Fitzgerald, Guggenheim, Raymond James, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ANIP.

What is the current price target for ANI Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for ANI Pharmaceuticals in the last year. Their average twelve-month price target is $46.00, suggesting a possible upside of 39.4%. Guggenheim has the highest price target set, predicting ANIP will reach $58.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $40.00 for ANI Pharmaceuticals in the next year.
View the latest price targets for ANIP.

What is the current consensus analyst rating for ANI Pharmaceuticals?

ANI Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANIP will outperform the market and that investors should add to their positions of ANI Pharmaceuticals.
View the latest ratings for ANIP.

What other companies compete with ANI Pharmaceuticals?

How do I contact ANI Pharmaceuticals' investor relations team?

ANI Pharmaceuticals' physical mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company's listed phone number is 218-634-3500 and its investor relations email address is [email protected] The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.